CA2941703A1 - Cancer stem cell targeting compounds - Google Patents

Cancer stem cell targeting compounds Download PDF

Info

Publication number
CA2941703A1
CA2941703A1 CA2941703A CA2941703A CA2941703A1 CA 2941703 A1 CA2941703 A1 CA 2941703A1 CA 2941703 A CA2941703 A CA 2941703A CA 2941703 A CA2941703 A CA 2941703A CA 2941703 A1 CA2941703 A1 CA 2941703A1
Authority
CA
Canada
Prior art keywords
compound
cancer
pharmaceutically acceptable
stem cells
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2941703A
Other languages
English (en)
French (fr)
Inventor
Sangeeta Srivastava
Maithili ATHAVALE
Kedar SHUKRE
Gayatri MORE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Godavari Biorefineries Ltd
Original Assignee
Godavari Biorefineries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Godavari Biorefineries Ltd filed Critical Godavari Biorefineries Ltd
Publication of CA2941703A1 publication Critical patent/CA2941703A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2941703A 2014-03-11 2015-03-11 Cancer stem cell targeting compounds Abandoned CA2941703A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN815/MUM/2014 2014-03-11
PCT/IN2015/050020 WO2015136557A2 (en) 2014-03-11 2015-03-11 Cancer stem cell targeting compounds
IN815MU2014 IN2014MU00815A (https=) 2014-03-11 2015-03-11

Publications (1)

Publication Number Publication Date
CA2941703A1 true CA2941703A1 (en) 2015-09-17

Family

ID=54072550

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2941703A Abandoned CA2941703A1 (en) 2014-03-11 2015-03-11 Cancer stem cell targeting compounds

Country Status (9)

Country Link
US (1) US20180169100A1 (https=)
EP (1) EP3116867A4 (https=)
JP (1) JP2017507969A (https=)
AU (1) AU2015228386A1 (https=)
CA (1) CA2941703A1 (https=)
IL (1) IL247723A0 (https=)
IN (1) IN2014MU00815A (https=)
MX (1) MX2016011675A (https=)
WO (1) WO2015136557A2 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009920B1 (ru) * 2003-08-29 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения пиримидотиофена
GB0416168D0 (en) * 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2473054B1 (en) * 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia

Also Published As

Publication number Publication date
IN2014MU00815A (https=) 2015-09-25
JP2017507969A (ja) 2017-03-23
IL247723A0 (en) 2016-11-30
EP3116867A2 (en) 2017-01-18
MX2016011675A (es) 2016-12-14
US20180169100A1 (en) 2018-06-21
AU2015228386A1 (en) 2016-09-22
EP3116867A4 (en) 2017-10-18
WO2015136557A3 (en) 2015-11-12
WO2015136557A9 (en) 2022-05-27
WO2015136557A2 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
US20250188074A1 (en) Ptpn11 inhibitors
TWI805664B (zh) Ｔｌｒ７/８拮抗劑及其用途
US11542251B2 (en) IRAK degraders and uses thereof
CN119278199A (zh) 驱动蛋白kif18a抑制剂及其应用
JP2017511360A (ja) Ｍｄｍ２阻害剤及びそれを使用する治療方法
US8435976B2 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
WO2014040555A1 (zh) 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
CN106488910A (zh) Kras g12c的抑制剂
US20130281396A1 (en) Treatment of diseases by epigenetic regulation
EP2609082A1 (de) Imidazo [4,5-c]chinoline als dna-pk-inhibitoren
EP2588457A1 (de) Pyrazolochinoline
CN105189486B (zh) 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
CA2922542A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
US9724331B2 (en) Use of maleimide derivatives for preventing and treating leukemia
CA2884832C (en) Means and method for treating solid tumours
WO2020156479A1 (zh) 环丙烯并苯并呋喃取代的氮杂芳基化合物、其中间体、制备方法及应用
Shejale et al. Synthesis, characterization and evaluation of antitubercular and analgesic activity of some novel pyrazolopyrimidine and pyrazolopyridine derivatives
CA2941703A1 (en) Cancer stem cell targeting compounds
WO2022132623A1 (en) Small molecules as larp1 ligands
US20170022215A1 (en) Compounds for Eradicating or Inhibiting Proliferation of Cancer Stem Cells
US20230226196A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
US20230346814A1 (en) Methods of modulating t-cell activation using carboranes and carborane analogs
TW202409026A (zh) 苯并噻唑化合物及其使用方法
CN119403788A (zh) 新的ras抑制剂

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831